A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
A Phase II Study of JS212 Monotherapy or Combination Therapy With JS207 or JS001 in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The study consists of 2 parts. Both parts consist of safety run-in period and cohort expansion period. Safety run-in period will enroll those who have received only 1 line of prior systemic standard treatment. Cohort expansion period will enroll those are treated naive or recived treatment in adjuvant phase.
Part 1 will receive JS212 monotherapy or combination therapy with JS207, based on the PD-L1 expression. Part 2 will receive JS212 in combination with JS001.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Chaoqiang Yang, PM
- Telefonnummer: 18252095266
- E-mail: chaoqiang_yang@junshipharma.com
Studiesteder
-
-
-
Beijing, Kina
- Rekruttering
- Peking University People's Hospital
-
Kontakt:
- Shu Wang, PhD.
- Telefonnummer: 13801080201
- E-mail: dr.wangshu@263.net
-
Ledende efterforsker:
- Shu Wang, Ph.D.
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100144
- Ikke rekrutterer endnu
- Peking University Shougang Hospital
-
Kontakt:
- Xueli Mo, Master
- Telefonnummer: 13699180225
- E-mail: xuelimo@hotmail.com
-
Ledende efterforsker:
- Xueli Mo, Master
-
Beijing, Beijing Municipality, Kina, 100071
- Ikke rekrutterer endnu
- The Fifth Medical Center of Chinese PLA General Hospital
-
Kontakt:
- Shaohua Zhang, Doctor
- Telefonnummer: 13311591557
- E-mail: zhangsh19760428@163.com
-
Ledende efterforsker:
- Shaohua Zhang, Doctor
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350000
- Ikke rekrutterer endnu
- Fujian Cancer Hospital
-
Kontakt:
- Fan Wu, Ph.D.
- Telefonnummer: 13859082118
- E-mail: wufan_fj@163.com
-
Ledende efterforsker:
- Fan Wu, Ph.D.
-
-
Gansu
-
Lanzhou, Gansu, Kina, 730000
- Ikke rekrutterer endnu
- The First Hospital of Lanzhou University
-
Kontakt:
- Xiaoling Ling, Ph.D.
- Telefonnummer: 18693165668
- E-mail: lingxiaolingedu@163.com
-
Ledende efterforsker:
- Xiaoling Ling, Ph.D.
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- Ikke rekrutterer endnu
- Sun Yat-sen University Cancer Center
-
Kontakt:
- Shusen Wang, Ph.D.
- Telefonnummer: 13926168469
- E-mail: wangshs2019@163.com
-
Ledende efterforsker:
- Shusen Wang, Ph.D.
-
Guangzhou, Guangdong, Kina, 510080
- Ikke rekrutterer endnu
- Guangdong General Hospital
-
Kontakt:
- Kun Wang, Ph.D.
- Telefonnummer: 13922118086
- E-mail: bzwangkun@163.com
-
Ledende efterforsker:
- Kun Wang, Ph.D.
-
-
Guizhou
-
Guiyang, Guizhou, Kina, 550004
- Ikke rekrutterer endnu
- The Affiliated Hospital of Guizhou Medical University
-
Kontakt:
- Shu Liu, Ph.D.
- Telefonnummer: 13908516963
- E-mail: drliushu@163.com
-
Ledende efterforsker:
- Shu Liu, Ph.D.
-
Guiyang, Guizhou, Kina, 550001
- Ikke rekrutterer endnu
- The Affiliated Cancer Hospital of Guizhou Medical University City: Guiyang
-
Kontakt:
- Zhihong Wang, Bachelor
- Telefonnummer: 13595159308
- E-mail: Wzh1968626@sina.com
-
Ledende efterforsker:
- Zhihong Wang, Bachelor
-
-
Hebei
-
Baoding, Hebei, Kina, 071000
- Ikke rekrutterer endnu
- Affiliated Hospital of Hebei University
-
Kontakt:
- Hua Yang, Ph.D.
- Telefonnummer: 18603120729
- E-mail: docyh@163.com
-
Ledende efterforsker:
- Hua Yang, Ph.D.
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150081
- Ikke rekrutterer endnu
- Harbin Medical University Cancer Hospital
-
Kontakt:
- Wenhui Zhao, Ph.D.
- Telefonnummer: 18745177632
- E-mail: zhaowenhui1977@163.com
-
Ledende efterforsker:
- Wenhui Zhao, Ph.D.
-
-
Henan
-
Zhengzhou, Henan, Kina, 450001
- Ikke rekrutterer endnu
- The First Affiliated Hospital of Zhengzhou University
-
Kontakt:
- Hong Zong, Ph.D.
- Telefonnummer: 13623586882
- E-mail: zonghong522@126.com
-
Ledende efterforsker:
- Hong Zong, Ph.D.
-
Zhengzhou, Henan, Kina, 450002
- Ikke rekrutterer endnu
- Henan Cancer Hospital
-
Kontakt:
- Min Yan, Ph.D.
- Telefonnummer: 15713857388
- E-mail: ym200678@126.com
-
Ledende efterforsker:
- Min Yan, Ph.D.
-
-
Hubei
-
Wuhan, Hubei, Kina, 430079
- Ikke rekrutterer endnu
- Hubei Cancer Hospital
-
Kontakt:
- Xinhong Wu, Ph.D.
- Telefonnummer: 18602726300
- E-mail: Xinhongwuhbch@163.com
-
Ledende efterforsker:
- Xinhong Wu, Ph.D.
-
-
Hunan
-
Changde, Hunan, Kina, 415003
- Ikke rekrutterer endnu
- The First People's Hospital of Changde City
-
Kontakt:
- Hui Li, Ph.D.
- Telefonnummer: 15886648808
- E-mail: 373099626@qq.com
-
Ledende efterforsker:
- Hui Li, Ph.D.
-
Changsha, Hunan, Kina, 410013
- Ikke rekrutterer endnu
- Hunan Cancer Hospital
-
Kontakt:
- Quchang Ouyang, Ph.D.
- Telefonnummer: 13973135318
- E-mail: oyqc1969@126.com
-
Ledende efterforsker:
- Quchang Ouyang, Ph.D.
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210029
- Ikke rekrutterer endnu
- Jiangsu Province Hospital
-
Kontakt:
- Wei Li, Ph.D.
- Telefonnummer: 13851603656
- E-mail: real.lw@163.com
-
Ledende efterforsker:
- Wei Li, Ph.D.
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330009
- Ikke rekrutterer endnu
- Nanchang People's Hospital
-
Kontakt:
- Wenyan Chen, Bachelor
- Telefonnummer: 18679168977
- E-mail: chenwenyannc2013@163.com
-
Ledende efterforsker:
- Wenyan Chen, Bachelor
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Ikke rekrutterer endnu
- The First Hospital of Jilin University
-
Kontakt:
- Lihua Kang, Ph.D.
- Telefonnummer: 13504334518
- E-mail: kanglihua961002@163.com
-
Ledende efterforsker:
- Lihua Kang, Ph.D.
-
Changchun, Jilin, Kina, 130012
- Ikke rekrutterer endnu
- Jilin Provincial Cancer Hospital
-
Kontakt:
- Fei Chen, Master
- Telefonnummer: 18604430968
- E-mail: Email:flyrcf@163.com
-
Ledende efterforsker:
- Fei Chen, Master
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110022
- Ikke rekrutterer endnu
- Shengjing Hospital of China Medical University
-
Kontakt:
- Xihe Zhao, Ph.D.
- Telefonnummer: 18940259508
- E-mail: zhaoxh@sj-hospital.org
-
Ledende efterforsker:
- Xihe Zhao, Ph.D.
-
Shenyang, Liaoning, Kina, 110042
- Ikke rekrutterer endnu
- Cancer Hospital of Dalian University of Technology(Liaoning Cancer Hospital & Institute)
-
Kontakt:
- Tao Sun, Ph.D.
- Telefonnummer: 13940404526
- E-mail: lnzlrxnsy@163.com
-
Ledende efterforsker:
- Tao Sun, Ph.D.
-
Shenyang, Liaoning, Kina, 110167
- Ikke rekrutterer endnu
- Introduction to the First Affiliated Hospital of China Medical University
-
Kontakt:
- Yuee Teng, Ph.D.
- Telefonnummer: 13591639797
- E-mail: tengyuee517@yahoo.com.cn
-
Ledende efterforsker:
- Yuee Teng, Ph.D.
-
-
Ningxia
-
Yinchuan, Ningxia, Kina, 750000
- Ikke rekrutterer endnu
- General Hospital of Ningxia Medical University
-
Kontakt:
- Ye Lv, Bachelor
- Telefonnummer: 18709515757
- E-mail: liuweilvye@yeah.net
-
Ledende efterforsker:
- Ye Lv, Bachelor
-
-
Shandong
-
Jinan, Shandong, Kina, 250117
- Ikke rekrutterer endnu
- Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
-
Kontakt:
- Qi Dang, Master
- Telefonnummer: 15318816098
- E-mail: dangqi123456@126.com
-
Kontakt:
- Huihui Li, Ph.D.
- Telefonnummer: 15553103209
- E-mail: 15553103209@163.com
-
Ledende efterforsker:
- Huihui Li, Ph.D.
-
Jining, Shandong, Kina, 272000
- Ikke rekrutterer endnu
- Affiliated Hospital of Jining Medical University
-
Kontakt:
- Changping Shan, Master
- Telefonnummer: 18678766865
- E-mail: scp9933@163.com
-
Ledende efterforsker:
- Changping Shan, Master
-
Qingdao, Shandong, Kina, 266000
- Ikke rekrutterer endnu
- The Affiliated Hospital of Qingdao University
-
Kontakt:
- Haibo Wang, Ph.D.
- Telefonnummer: 18661805787
- E-mail: hbwangqy@126.com
-
Ledende efterforsker:
- Haibo Wang, Ph.D.
-
Weifang, Shandong, Kina, 261000
- Ikke rekrutterer endnu
- Weifang People's Hospital
-
Kontakt:
- Wenhui Wang, Ph.D.
- Telefonnummer: 18605368857
- E-mail: wwh8857@163.com
-
Ledende efterforsker:
- Wenhui Wang, Ph.D.
-
-
Shanxi
-
Taiyuan, Shanxi, Kina, 030013
- Ikke rekrutterer endnu
- Shanxi Cancer Hospital
-
Kontakt:
- Guohui Han, Ph.D.
- Telefonnummer: 13754858188
- E-mail: 13754858188@163.com
-
Ledende efterforsker:
- Guohui Han, Ph.D.
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610072
- Ikke rekrutterer endnu
- Sichuan Provincial People's Hospital
-
Kontakt:
- Jing Luo, Ph.D.
- Telefonnummer: 18981838521
- E-mail: jingluopi@163.com
-
Ledende efterforsker:
- Jing Luo, Ph.D.
-
Mianyang, Sichuan, Kina
- Ikke rekrutterer endnu
- Mianyang Central Hospital
-
Kontakt:
- Zhen zhang, Master
- Telefonnummer: 13778159530
- E-mail: jiangzhangtong@sina.com
-
Ledende efterforsker:
- Zhen Zhang, Master
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female age 18-70 years old;
- Voluntary participation in clinical study;
- Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);
- No prior systemic antitumor therapy for locally advanced or Metastatic TNBC(cohort expansion period); only one line of prior systemetic treatment for locally advanced or metastatic TNBC;
- Adequate organ function;
- ECOG performance status of 0 or 1;
- Life expectancy 12 weeks;
- Measurable disease, as defined by RECIST v1.1;
Exclusion Criteria:
- Untreated or active central nervous system (CNS) metastases;
- Uncontrolled pleural effusion, pericardial effusion or ascites;
- Tumor encasement of important vessels or significant necrosis and cavitation that may cause a risk of hemorrhage;
- History of significant bleeding tendency or severe coagulation disorder;
- Uncontrolled hypertension;
- Active autoimmune diseases requiring systemic treatmen within 2 years prior to the first dose;
- History of interstitial lung disease or previous Noninfectious pneumonitis treated with corticosteroids, or evidence of active Pneumonia in radiology on screening period;
- History of immunodeficiency. Presence of active tuberculosis, hepatitis B, or hepatitis C;
- Severe cardiovascular disease;
- Serious infection (CTCAE 6.0 Grade>2) within 28 days prior to the first dose of study drug;
- Previous treatment of any anti-VRGF drugs targeting VEGF (part 1) or ADC drugs targeting EGFR and/or HER3;
- History of another malignancy within 5 years before the first dose of study drug;
- Not suitable to receive study treatment for other conditions as per investigator;
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Cohort A
JS212 in combination with JS207,CPS≥10 |
JS212 and JS207 will be administered intravenously on D1, Q3W |
|
Eksperimentel: Cohort B
JS212 monotherapy, CPS<10 |
JS212 will be administered intravenously on D1,Q3W |
|
Eksperimentel: Cohort C
JS212 in combination with JS207, CPS<10 |
JS212 and JS207 will be administered intravenously on D1, Q3W |
|
Eksperimentel: Cohort D
JS212 in combination with JS001 |
JS212 and JS001 will be administered intravenously on D1, Q3W |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective response rate(ORR)
Tidsramme: 24 months
|
Objective response rate(ORR) evaluated based on RECIST v1.1 |
24 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of response (DoR)
Tidsramme: 24 months
|
Duration of response (DoR) evaluated based on RECIST v1.1 |
24 months
|
|
Disease control rate (DOR)
Tidsramme: 24 months
|
Disease control rate (DOR)evaluated based on RECIST v1.1 |
24 months
|
|
Progression free survival (PFS)
Tidsramme: 24 months
|
Progression free survival (PFS) evaluated based on RECIST v1.1 |
24 months
|
|
Overall Survival (OS)
Tidsramme: 36 months
|
Overall Survival (OS)evaluated based on RECIST v1.1 |
36 months
|
|
Adverse Events
Tidsramme: 24 months
|
Incidence and severity of Adverse Events(AEs)according to NCI-CTCAE v6.0 |
24 months
|
|
Immunogenicity
Tidsramme: 24 months
|
The incidence of Nab(if applicable) of JS212 and JS207 |
24 months
|
|
Plasma concentrations
Tidsramme: 2 years
|
Plasma concentrations of JS207 and 9MW2821 |
2 years
|
|
PD-L1 expression
Tidsramme: 2 years
|
The correlation between PD-L1 expression in tumor tissue and therapeutic efficacy |
2 years
|
|
EGFR/HER expression
Tidsramme: 2 years
|
The correlation between EGFR/HER3 expression in tumor tissue and therapeutic efficacy |
2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- JS212-009-II-BC
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .